Q0240 HCPCS Level II code: Injection, casirivimab and imdevimab, 600 mg
CMS terminated Q0240: its last date of service was Dec 12, 2024. It stays here for looking up older claims; newer services need a current code.
Official description
Q0240Injection, casirivimab and imdevimab, 600 mg
Short description: Casirivi and imdevi 600 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with Q0240 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Vaccinations
- Type of service
- Pneumococcal/flu vaccine
- BETOS category
- Immunizations/Vaccinations
- Added
- Jul 30, 2021
- Terminated after
- Dec 12, 2024
Where Q0240 sits
- 1Q codesTemporary codes
- 2Terminated Q0240Injection, casirivimab and imdevimab, 600 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q0240 still valid?
No. CMS terminated Q0240; its last date of service was Dec 12, 2024. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q0240?
CMS lists Q0240’s Medicare coverage as “Carrier judgment” and its pricing as “Vaccinations”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q0240
All Q codesQ0224Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2…Q0234Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive…Q0235Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are…Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive…Q0238Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive…Q0239Injection, bamlanivimab-xxxx, 700 mgQ0243Injection, casirivimab and imdevimab, 2400 mgQ0244Injection, casirivimab and imdevimab, 1200 mgQ0245Injection, bamlanivimab and etesevimab, 2100 mgQ0247Injection, sotrovimab, 500 mgQ0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require…Q0477Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only